WHO WE ARE

Company motto

Potentiates vaccine for
global immunization






Vision statement

Innovative technology for novel vaccine


Cold chain free nasal vaccine


Peptide vaccine without pathogen


Low cost T Cell therapy for cancer
and infectious disease







Business area/NAVI

T-cell Therapy, IRI Pharma sipn off, Animal vaccine, human vaccine, cancer vaccine










Members of NAVI

Dongho Kim, Ph.D. CEO

Ph.D. University of Texas at Austin
Postdoc. in Beckman Research Institute of City of Hope
Staff Scientist/Director of RNAi core of Beckman Research Institute of COH
CEO and Founder of Cellonex, Biofactories, Genolution, IRI Pharma, NA Vaccine Institute
Adjunct Professor, POSTECH

Myung-soo Kang, Ph.D. COO

Seoul National University
Instructor at Harvard Medical School
Professor at Samsung Medical Center
Director at Intron Biotechnology

Eui Ho Kim, Ph.D. CTO

Ph.D. University of Wisconsin-Madison, Immunology
Postdoc. Emory University, Vaccine immunology
Research Fellow at NIEHS, National Institutes of Health

John Rossi, Ph.D.

Board director of scientific advisory
Chair and Professor, Department of Molecular and Cellular Biology, Beckman Research Institute of the City of Hope.
A World Leader in RNAi and in clinical research with nucleic acids.
Co-founder of Dicerna Pharmaceuticals, Calando Pharmaceuticals, Inc. 

John Killmer, Ph.D.

Vice president: strategic alliance
Specialty in clinical trials. 30 years in biotechnology industries including 25 years with Monsanto. P&L, R&D and product management as President of Monsanto China.  

Won Jong Kim, Ph.D.

Scientific Advisor Ph.D.
Tokyo Institute of Technology Postdoc. in University of Utah Mueunjae Chaired Professor, POSTECH  

Taerim Yun, CFO

 Sungkyunkwan University, MBA
SK Telecom Team Leader , SK Planet Project Leader
Specialist in Finance, M&A, Venture Fund Investment, Business Portfolio Management